Compare Marriott International Inc (MAR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Marriott International Inc trades at $373.11 (market cap $96.87B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Marriott International Inc is far larger — about 12.9× Spyre Therapeutics Inc. Common Stock's market cap, and Marriott International Inc pays a 0.79% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MAR | SYRE | |
|---|---|---|
Market Cap | $96.87B | $7.52B |
Volume | 755,878 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $108.92 |
52-Week Low | $259.04 | $22.18 |
Typical Hold Time | 164 Days | 0 Days |
Enterprise Value | $114.19B | $6.52B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $371.82, up 0.68% today, near its resistance at $372. The stock shows bullish technical signals with strong moving averages, though the RSI indicates mild overbought conditions. Fundamentally, revenue grew to $26.19B in 2025 with a net income margin of 9.62%, but the P/E of 38.46 and P/B of 443.63 reflect premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share.
The outlook for MAR is positive, supported by robust travel demand and strategic initiatives like new technology partnerships. However, risks include high debt levels, with debt-to-asset ratio rising to 55.17% in 2024, and sensitivity to economic cycles. Analysts maintain a consensus price target of $388.93, suggesting moderate upside, but investors should weigh valuation concerns against growth prospects in the hospitality sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
